Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Caspofungin: an overview.

Vicki A Morrison1

  • 1University of Minnesota, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA. morri002@tc.umn.edu

Expert Review of Anti-Infective Therapy
|October 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303.

Journal of geriatric oncology·2025
Same author

Treatment of Acute Myeloid Leukemia in the Community Setting.

The oncologist·2024
Same author

Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer.

JCO oncology practice·2022
Same author

Geriatric assessment in older adults with non-Hodgkin lymphoma: A Young International Society of Geriatric Oncology (YSIOG) review paper.

Journal of geriatric oncology·2022
Same author

Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage.

Cancer treatment and research communications·2021
Same author

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2021
Same journal

<i>Pneumocystis</i> pneumonia in non-HIV immunocompromised patients in 2026: evolving therapeutic standards.

Expert review of anti-infective therapy·2026
Same journal

Asymptomatic is not silent: proposal of HTLV-1-associated multiple inflammatory disease as an early neuroinflammatory state.

Expert review of anti-infective therapy·2026
Same journal

The endocarditis team: a review.

Expert review of anti-infective therapy·2026
Same journal

Synergistic antifungal effects and potential mode of action of crisaborole combined with azoles against drug-resistant <i>Candida albicans</i>.

Expert review of anti-infective therapy·2026
Same journal

Anti-infective therapy and novel treatment options for coccidioidomycosis.

Expert review of anti-infective therapy·2026
Same journal

Intensivists' practices and perceptions regarding β-lactam prescribing and monitoring in intensive care units: a cross-sectional survey.

Expert review of anti-infective therapy·2026
See all related articles

Echinocandins, like caspofungin, are novel intravenous antifungal drugs inhibiting fungal cell wall synthesis. They offer therapeutic options for various serious fungal infections, advancing patient care despite lacking oral formulations.

Area of Science:

  • Pharmacology
  • Mycology

Background:

  • Echinocandins represent a novel class of antifungal agents introduced in the last decade.
  • These lipopeptide agents function by noncompetitively inhibiting the synthesis of 1,3-beta-glucans, essential fungal cell wall components.

Purpose of the Study:

  • To review the role and applications of echinocandins, specifically caspofungin, in treating serious fungal infections.
  • To highlight the mechanism of action, therapeutic uses, limitations, and overall significance of caspofungin.

Main Methods:

  • Literature review of echinocandin antifungal agents, focusing on caspofungin.
  • Analysis of clinical applications, mechanism of action, and limitations based on available data.

Main Results:

  • Caspofungin (Cancidas) is the first approved echinocandin, available only intravenously.

Related Experiment Videos

  • It is effective for candidal esophagitis, deep candidal infections, and as an alternative for Aspergillus infections, particularly in salvage therapy.
  • Also used for empiric therapy in febrile neutropenia, with anecdotal support for less common fungal infections.

    • Conclusions:

    • Echinocandins, exemplified by caspofungin, are a significant advancement in managing serious fungal infections.
    • A key limitation is the absence of an oral formulation, though it can be used in combination antifungal regimens.